Marinus Verwijs - Nov 1, 2023 Form 4 Insider Report for Aerovate Therapeutics, Inc. (AVTE)

Role
CHIEF TECHNOLOGY OFFICER
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Stock symbol
AVTE
Transactions as of
Nov 1, 2023
Transactions value $
-$10,149
Form type
4
Date filed
11/3/2023, 05:00 PM
Previous filing
May 5, 2023
Next filing
Jan 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Sale -$10.1K -970 -100% $10.46 0 Nov 1, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to E*TRADE Securities LLC's Quicksale Trading Plan elected by the reporting person on July 11, 2022.
F2 Includes 970 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2023 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.96 to $10.78, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.